modelHydromorphone
Extends from Pharmacolibrary.Drugs.ATC.N.N02AA03.
Information
| name: | Hydromorphone | |
| ATC code: | N02AA03 | route: | oral |
| compartments: | 1 | |
| dosage: | 8 | mg |
| volume of distribution: | 1.22 | L |
| clearance: | 1.96 | L/h/kg |
| other parameters in model implementation | ||
Hydromorphone is a potent opioid analgesic used to relieve moderate to severe pain. It acts primarily as a mu-opioid receptor agonist and is approved for use in many countries. Hydromorphone is available in various formulations including oral, intravenous, and rectal preparations. It is commonly used in both acute and chronic pain management, particularly in hospital settings.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers following a single oral dose.
References
Thigpen, JC, et al., & Harirforoosh, S (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. European journal of drug metabolism and pharmacokinetics 44(5) 591–609. DOI:10.1007/s13318-019-00552-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31006834
Nakatani, T, et al., & Saito, Y (2023). Steady-State Pharmacokinetics of Intravenous Hydromorphone in Japanese Patients With Renal Impairment and Cancer Pain. Journal of palliative medicine 26(6) 768–775. DOI:10.1089/jpm.2022.0289 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36579915
Rodieux, F, et al., & Samer, CF (2022). Hydromorphone Prescription for Pain in Children-What Place in Clinical Practice?. Frontiers in pediatrics 10 842454–None. DOI:10.3389/fped.2022.842454 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35547539
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)